Sana Biotechnology Inc (SANA)
9.89
+0.27
(+2.81%)
USD |
NASDAQ |
May 02, 15:15
Sana Biotechnology Cash from Financing (Quarterly): 1.718M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.718M |
| September 30, 2023 | 0.187M |
| June 30, 2023 | 29.50M |
| March 31, 2023 | 0.236M |
| December 31, 2022 | 1.061M |
| September 30, 2022 | 1.621M |
| June 30, 2022 | 1.579M |
| March 31, 2022 | 0.652M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.119M |
| September 30, 2021 | 1.596M |
| June 30, 2021 | 0.333M |
| March 31, 2021 | 626.70M |
| December 31, 2020 | 0.103M |
| September 30, 2020 | 0.004M |
| June 30, 2020 | 435.58M |
| March 31, 2020 | 0.002M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.002M
Minimum
Mar 2020
626.70M
Maximum
Mar 2021
69.00M
Average
1.32M
Median
Cash from Financing (Quarterly) Benchmarks
| Rocket Pharmaceuticals Inc | 0.391M |
| Solid Biosciences Inc | 0.505M |
| Dyne Therapeutics Inc | 0.147M |
| Taysha Gene Therapies Inc | -4.248M |
| Tenaya Therapeutics Inc | 0.371M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -51.96M |
| Cash from Investing (Quarterly) | 15.31M |
| Free Cash Flow | -273.61M |
| Free Cash Flow Per Share (Quarterly) | -0.3345 |
| Free Cash Flow Yield | -14.16% |